文献速递类风湿关节炎脊柱关节炎其他结缔组织病

两种阿达木单抗生物类似药在1318例真实世界炎症性风湿病患者中的比较效果:全国性观察性研究模拟随机临床试验

Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial.
PubMed 文献 · Ann Rheum Dis · 2021-04-29

丹麦全国强制性从原研阿达木单抗切换至生物类似药,东部地区使用GP2017,西部地区使用SB5。基于DANBIO登记模拟随机试验分析1318例类风湿关节炎(RA)、银屑病关节炎(PsA)或中轴型脊柱关节炎(AxSpA)患者,GP2017较SB5的1年停药风险更低(HR 0.60;95%CI 0.42-0.86),6个月缓解率更高(OR 1.72;95%CI 1.25-2.37)。

要点

  • 强制性切换后GP2017较SB5的1年治疗留存更优,停药风险HR 0.60(95%CI 0.42-0.86)。
  • GP2017较SB5的6个月缓解率更高,OR 1.72(95%CI 1.25-2.37)。
  • 分层分析结果相似,RA亚组差异有统计学意义。

核心结论

  • GP2017与SB5在原研阿达木单抗强制性切换后常规诊疗中显示效果差异,可能反映真实差异,但不能排除辅料差异、集群差异及残余混杂。

研究设计与样本

  • 基于DANBIO登记的前瞻性观察性队列研究,利用地理集群伪随机化模拟随机临床试验。
  • 1570例符合条件患者中1318例完成切换并纳入分析(467例RA/321例PsA/530例AxSpA),623例(47%)切换至GP2017,695例(53%)切换至SB5。

主要发现

  • 两种生物类似药合计1年治疗留存率为89.5%。
  • GP2017较SB5的估计停药风险更低(HR 0.60;95%CI 0.42-0.86)。
  • GP2017较SB5的6个月缓解率更高(OR 1.72;95%CI 1.25-2.37)。
  • 分层分析结果相似,RA亚组差异有统计学意义。
  • 1年内GP2017和SB5的停药率分别为8.5%和12.9%(主要因疗效不足和不良事件),其中48例(3.6%)回切至原研药。

关键数值与推荐

  • 主要结局为校正后1年治疗留存(Cox回归)。
  • 次要结局为6个月缓解率(logistic回归)、停药原因及回切至原研药情况(总体及按适应症分层)。

临床怎么用

  • 在强制性从原研阿达木单抗切换至生物类似药的临床场景中,GP2017相对于SB5可能具有更优的1年治疗留存和6个月缓解率,但需结合辅料、地区差异及残余混杂谨慎解读。

局限性

  • 观察性设计无法完全排除残余混杂;两个地理集群在登记实践上存在差异;辅料差异等可能影响结果;不能排除集群间其他差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: In 2018, a nationwide mandatory switch from originator to biosimilar adalimumab was conducted in Denmark. The available biosimilar was GP2017 (Hyrimoz) in Eastern regions and SB5 (Imraldi) in Western regions. We aimed to assess the comparative effectiveness of GP2017 versus SB5 in patients with rheumatoid arthritis (RA)/psoriatic arthritis (PsA)/axial spondyloarthritis (AxSpA). METHODS: Observational cohort study based on the DANBIO registry with geographical cluster pseudo-randomisation, analysed by emulating a randomised clinical trial. Main outcome was adjusted 1-year treatment retention (Cox regression). Furthermore, 6 months' remission rates (logistic regression), reasons for withdrawal and back-switching to originator were investigated (overall and stratified by indication). RESULTS: Overall, of 1570 eligible patients, 1318 switched and were included (467 RA/321 PsA/530 AxSpA); 623 (47%) switched to GP2017, 695 (53%) to SB5. Baseline characteristics of the two clusters were largely similar, but some differences in registration practice were observed. The combined 1-year retention rate for the two biosimilars was 89.5%. Compared with SB5, estimated risk of withdrawal for GP2017 was lower (HR 0.60; 95% CI 0.42 to 0.86) and 6 months' remission rate was higher (OR 1.72; 95% CI 1.25 to 2.37). Stratified analyses gave similar results (statistically significant for RA). During 1 year, 8.5% and 12.9% withdrew GP2017 and SB5, respectively (primarily lack of effect and adverse events), of whom 48 patients (3.6%) back-switched. CONCLUSION: This head-to-head comparison of GP2017 versus SB5 following a mandatory switch from the originator indicated differences in effectiveness in routine care. This may reflect a true difference, but other explanations, for example, differences in excipients, differences between clusters and residual confounding cannot be ruled out.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Nabi H, Georgiadis S, Loft AG, et al. Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial. Ann Rheum Dis. 2021. PMID: 33926921. doi:10.1136/annrheumdis-2021-219951

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。